Skip to content
10-Q

Quarterly Report

Tango Therapeutics, Inc. TNGX

0001193125-26-221656

← back to feed
Filed
May 13, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 6, 2026 144.65M sh
Shares Diluted Q1 2026 · Mar 31, 2026 143.58M sh
Shares Diluted Q1 2026 · Mar 31, 2025 110.3M sh
Capex Q1 2026 · Mar 31, 2026 −$2K
Capex Q1 2026 · Mar 31, 2025 $51K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$44.36M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$41.7M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $157.83M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $112.28M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $58.43M
Stockholders Equity Q1 2026 · Mar 31, 2026 $391.51M
Stockholders Equity Q1 2026 · Dec 31, 2025 $346.18M
Stockholders Equity Q1 2026 · Mar 31, 2025 $166.76M
Stockholders Equity Q1 2026 · Dec 31, 2024 $199.52M
Current Liabilities Q1 2026 · Mar 31, 2026 $14.33M
Current Liabilities Q1 2026 · Dec 31, 2025 $21.68M
Total Liabilities Q1 2026 · Mar 31, 2026 $44.29M
Total Liabilities Q1 2026 · Dec 31, 2025 $52.51M
Current Assets Q1 2026 · Mar 31, 2026 $392.33M
Current Assets Q1 2026 · Dec 31, 2025 $353.76M
Total Assets Q1 2026 · Mar 31, 2026 $435.79M
Total Assets Q1 2026 · Dec 31, 2025 $398.69M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.32
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.36
Eps Basic Q1 2026 · Mar 31, 2026 −$0.32
Eps Basic Q1 2026 · Mar 31, 2025 −$0.36
Sga Expense Q1 2026 · Mar 31, 2026 $15.24M
Sga Expense Q1 2026 · Mar 31, 2025 $11.48M
Rd Expense Q1 2026 · Mar 31, 2026 $33.53M
Rd Expense Q1 2026 · Mar 31, 2025 $36.44M
Net Income Q1 2026 · Mar 31, 2026 −$45.51M
Net Income Q1 2026 · Mar 31, 2025 −$39.88M
Operating Income Q1 2026 · Mar 31, 2026 −$48.77M
Operating Income Q1 2026 · Mar 31, 2025 −$42.53M
Revenue Q1 2026 · Mar 31, 2026 $0
Revenue Q1 2026 · Mar 31, 2025 $5.39M